Friday, April 15, 2016
Cydan Development, an orphan drug accelerator dedicated to creating therapies that improves the lives of people living with rare genetic diseases, has launched Imara. This is the second orphan drug company launched by Cydan since 2015. Imara will develop IMR-687, a disease-modifying therapeutic selected specifically for the treatment of sickle cell disease and other hemoglobinopathies. IMR-687 was discovered by H. Lundbeck.